I think you are expecting too much from a single arm study on terminal "unresectable" pancreatic cancer patients. To make some sort of comparison you would have to go to the literature and look at trials of newer chemotherapy cocktails to see how many similar patients were downgraded from unresectable to resectable. My guess is a very small percentage because most of them will result in only an incremental increase in survival time Shrinking unresectable pancreatic cancer sufficiently to convert to potentially resectable with chemothrapy alone would likely gain quite a lot of attention in the literature.
Ann: PanCO Clinical Study on OncoSil Published in ESMO Open, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.025(2.43%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.05 | $1.00 | $41.05K | 40.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 1249 | 1 |
View Market Depth
| Last trade - 15.47pm 20/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |